You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on lung cancer.
Almac said that the assay will be used in a clinical study of repotrectinib (TPX-0005), an investigational, next-generation tyrosine kinase inhibitor.
The project, established by the National Cancer Center of Japan, screens target genes in lung cancer to advance the development of new drugs and diagnostics.
Never smokers make up an increasing portion of lung cancer patients, and researchers are working to tease out their genetic and environmental risk.
The protocol involves using CRISPR-Cas9 gene editing to knock out the NRF2 gene in KRAS-positive NSCLC patients who have become resistant to chemotherapy.
Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form.
Researchers used a genome-scale CRISPRi platform to identify genetic interactions with an inhibitor for a mutant form of KRAS in models of lung and pancreatic cancer.
The company said adopters are ordering tests in areas of great interest, like CTC and blood biomarker monitoring, despite a lack of reimbursement.
Shares jumped nearly 90 percent today after the firm said this morning that it has commercially launched its Target Selector NGS Lung Panel assay.
The firm is conducting validation studies on its lung cancer test and continues to anticipate commercializing it in the second half of this year.
In PNAS this week: sequencing of Globular Amphora culture individuals, characterization of effects of variants of unknown significance in EGFR, and more.
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.